MTOR and non-small cell lung carcinoma: As the first-generation mTOR inhibitor, rapamycin is currently being investigated in a clinical trial in patients with NSCLC in several combinations of sunitinib (NCT00555256) and afatinib (NCT00993499) [184,185].